Basilea Pharmaceutica AG /
Basilea announces that CHMP recommends approval of isavuconazole (CRESEMBA®) as
a treatment for invasive aspergillosis and mucormycosis in the European Union
. Processed and transmitted by NASDAQ OMX Corporate Solutions.
The issuer is solely responsible for the cont ...
↧